【摘要】 目的 探讨临床药师在疾病诊断相关分组(DRGs)支付模式下对药品成本管控的作用。方法 回顾性分析我院DRGs为周围性面神经麻痹的患者,按临床药师进行药品成本管控干预前后分为干预前组和干预后组,对比分析2组治疗效果、不良反应、人均住院费用、超限患者例数以及结余费用情况等。结果 干预前后2组患者治疗总有效率、Portmann评分和平均住院时间比较,差异均无统计学意义(P> 0.05);不良反应发生率干预前组高于干预后组(P <0.05);患者人均住院费用和药品费用以及超限患者例数干预后组较干预前组显著降低(P <0.05),结余费用及占比干预后组较干预前组显著升高(P <0.05)。结论 临床药师进行药品成本管控能够在保障疗效的基础上,可以降低患者住院费用,减少不良反应发生,对DRGs付费的顺利实施具有积极推进作用。更多还原

【Abstract】 AIM To explore the role of clinical pharmacists in drug cost control under diagnosis related groups(DRGs) payment model. METHODS Retrospective analysis was performed on patients with peripheral facial paralysis in DRGs in our hospital. According to the difference of drug treatment plan before and after drug cost control intervention by clinical pharmacists, patients were divided into pre-intervention group and post-intervention group, and the therapeutic effects, adverse drug reactions, average hospital expenses, number of super-standard patients and the cost balance of 2 groups were compared. RESULTS There was no significant difference in total effective rate, Portmann score and average length of hospitalization between 2 groups(P > 0.05). The incidence of adverse drug reactions was higher in the pre-intervention group than that in the post-intervention group(P < 0.05). Average hospital expenses, drug costs and number of super-standard patients in the post-intervention group were significantly lower than those in the pre-intervention group(P < 0.05), and surplus cost and proportion in post-intervention group were significantly higher than those in pre-intervention group(P < 0.05). CONCLUSION Drug cost control by clinical pharmacists can reduce the hospitalization costs of patients and the occurrence of adverse drug reactions on the basis of ensuring the efficacy, which plays a positive role in promoting the smooth implementation of DRGs payment.更多还原